RAD-140 (Testolone)
SARMTestolone · RAD
RAD-140 is considered the most potent SARM. Very favorable anabolic/androgenic ratio. Excellent strength and dry mass. Suppression similar to a low steroid dose.
Half-life
15–20 heures
Detection
2 semaines
Anabolic ratio
90
Androgenic ratio
1
Dosages
| Beginner | 5–10 mg/j |
| Intermediate | 10–15 mg/j |
| Advanced | 15–20 mg/j |
| Female | 2.5-5 mg/day (moderate virilization risk) |
Frequency : 1× / day
Effects
- Explosive strength ++
- Lean muscle mass
- Neuroprotection (studies)
- Training aggression
Side effects
- HPTA suppression
- Aggression
- Lethargy
- Potential hair shedding
Support supplements
Synergies & stacks
Avoid
- Doses > 20 mg/day (potential toxicity)
- Running without a planned PCT
Sources
Studies and scientific publications this guide relies on.
- Miller CP, Shomali M, Lyttle CR, et al. (2010). Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140. ACS Medicinal Chemistry Letters. doi: 10.1021/ml1002508
Article de design préclinique du RAD-140 (testolone) : caractérisation pharmacologique chez le primate non humain, ratio anabolique/androgénique très élevé en modèles animaux (~90/1 in vitro), sélectivité tissulaire muscle/os vs prostate — sans données cliniques humaines à la publication.
- Solomon ZJ, Mirabal JR, Mazur DJ, et al. (2019). Selective Androgen Receptor Modulators: Current Knowledge and Clinical Applications. Sexual Medicine Reviews. doi: 10.1016/j.sxmr.2018.09.006
Revue systématique : RAD-140 demi-vie ~15-20 h, suppression HPTA forte chez les utilisateurs amateurs (séries de cas), élévations ALAT documentées — recul clinique humain quasi-nul (un essai phase I oncologique en cours).
- Bhasin S, Jasuja R (2009). Selective androgen receptor modulators as function promoting therapies. Current Opinion in Clinical Nutrition and Metabolic Care. doi: 10.1097/MCO.0b013e32832a3d79
Revue mécanistique sur les SARMs : RAD-140 est un ligand non stéroïdien à profil tissu-sélectif très marqué in vitro, base du programme de développement clinique oncologique (cancer du sein AR-positif).
- Pope HG Jr, Wood RI, Rogol A, et al. (2014). Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement. Endocrine Reviews. doi: 10.1210/er.2013-1058
Énoncé Endocrine Society : les SARMs récents (RAD-140, S-23, YK-11) sont marqués par une absence presque totale de données cliniques humaines, recommandation de prudence accrue — extrapolation préclinique vers usage musculation non encadrée.
Related guides
Personalized tracking, dose-response curves and AI advice
Track your cycles with personalized curves based on your weight and profile, tailored AI advice, a daily journal and 59 blood markers.
Free 5-day trial — no credit card